Bupropion Hydrochloride/Dextromethorphan

NEW YORK, May 05, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will participate in the following upcoming investor conferences in May: BofA Securities 2026 Health Care ConferenceFireside Chat: Tuesday, May 12, 2026, at 8:40 a.m. PT in Las Vegas, NV 2026 RBC Capital Markets Global Healthcare ConferenceFireside Chat: Tuesday, May 19, 2026, at 1:35 p.m. ET in New York, NY Live webcasts of the presentations can be accessed on the “Webcasts & Presentations” page of the “Investors” section of the Company’s website at axsome.com. Replays of the webcasts will be available for approximately 30 days following each event. About Axsome Therapeutics Axsome Therapeutics is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. We deliver scientific breakthroughs by identifying critical gaps in care and develop differentiated products with a focus on novel mechanisms of action that enable meaningful advancements in patient outcomes. Our industry-leading neuroscience portfolio includes FDA-approved treatments for major depressive disorder, agitation associated with dementia due to Alzheimer’s disease, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine, as well as multiple novel product candidates addressing a broad range of serious neurological and psychiatric conditions that impact over 150 million people in the United States. Together, we are on a mission to solve some of the brain’s biggest problems so patients and their loved ones can flourish. For more information, please visit us at www.axsome.com and follow us on LinkedIn and X. Forward Looking Statements Certain matters discussed in this press release are “forward-looking statements”. The Company may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, the Company’s statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the commercial success of the Company’s SUNOSI®, AUVELITY®, and SYMBRAVO® products and the success of the Company’s efforts to obtain any additional indication(s) with respect to solriamfetol and/or AXS-05; the Company’s ability to maintain and expand payer coverage; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund the Company’s disclosed clinical trials, which assumes no material changes to the Company’s currently projected revenues or expenses), futility analyses and receipt of interim results, which are not necessarily indicative of the final results of the Company’s ongoing clinical trials, and/or data readouts, and the number or type of studies or nature of results necessary to support the filing of a new drug application (“NDA”) for any of the Company’s current product candidates; the Company’s ability to fund additional clinical trials to continue the advancement of the Company’s product candidates; the timing of and the Company’s ability to obtain and maintain U.S. Food and Drug Administration (“FDA”) or other regulatory authority approval of, or other action with respect to, the Company’s product candidates, including statements regarding the timing of any NDA submission; the Company’s ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the Company’s ability to successfully resolve any intellectual property litigation, and even if such disputes are settled, whether the applicable federal agencies will approve of such settlements; the successful implementation of the Company’s research and development programs and collaborations; the success of the Company’s license agreements; the acceptance by the market of the Company’s products and product candidates, if approved; the Company’s anticipated capital requirements, including the amount of capital required for the commercialization of SUNOSI, AUVELITY, and SYMBRAVO and for the Company’s commercial launch of its other product candidates, if approved, and the potential impact on the Company’s anticipated cash runway; the Company’s ability to convert sales to recognized revenue and maintain a favorable gross to net sales; unforeseen circumstances or other disruptions to normal business operations arising from or related to domestic political climate, geo-political conflicts or a global pandemic and other factors, including general economic conditions and regulatory developments, not within the Company’s control. The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances. Investors:Ashley DongSenior Director, Investor Relations(929) 687-1614adong@axsome.com Media:Darren OplandSenior Director, Corporate Communications(929) 837-1065dopland@axsome.com

药品营销避坑”试读： 药品导入期管理视频课（试听） 药品生命周期管理（案例） 药品立项需要注意什么（案例） 2026年4月30日华道生物宣布，万基奥仑赛注射液上市申请（NDA）已获得国家药品监督管理局（NMPA）的受理，拟用于难治复发非霍奇金淋巴瘤。 万基奥仑赛为靶向CD19的自体CAR-T细胞药物。目前国内共8款CAR-T细胞药物获批，包括阿基仑赛（Axicabtagene Ciloleucel）、瑞基奥仑赛（Relmacabtagene Autoleucel）、伊基奥仑赛（Equecabtagene Autoleucel）、纳基奥仑赛（Inaticabtagene Autoleucel）、泽沃基奥仑赛注射液（Zevorcabtagene Autoleucel）、西达基奥仑赛（Ciltacabtagene Autoleucel）、雷尼基奥仑赛（Ranicabtagene Autoleucel）、普基奥仑赛（Puzolcabtagene Autoleucel）。除伊基奥仑赛、泽沃基奥仑赛和西达基奥仑赛靶向B细胞成熟抗原（BCMA）外，其余均靶向CD19。 相关报道显示，与目前动辄CAR-T药物百万级定价不同，万基奥仑赛使用自主研发的无人化生产、全自动全封闭式细胞药物智能制造设备，预计上市后定价仅为20余万元。 推荐指数：★★ 推荐原因：随着不断获批上市，CAR-T细胞药物必将走向价格战。万基奥仑赛预计20余万元的定价，将击穿CAR-T细胞药物的地板价。 相关阅读： 先声药业申请IL-4Rα单抗乐德奇拜上市用于特应性皮炎 齐鲁制药艾帕洛利托沃瑞利单抗申请一线治疗转移性宫颈癌 鞍石生物安达艾替尼获批治疗EGFR ex20ins突变非小细胞肺癌 邦顺制药JAK2抑制剂贝泽昔替尼获批治疗骨髓纤维化 FDA批准强生卢美哌隆用于预防精神分裂症复发 首家，恩华药业申请抗抑郁药物右美沙芬安非他酮缓释片上市 晟斯生物申请上市长效重组凝血因子Ⅷ（FRSW117） 拜耳凝血因子ⅩⅠa抑制剂Asundexian国内申请用于预防卒中 FDA批准阿斯利康布地格福吸入气雾剂用于哮喘 三生艾曲泊帕乙醇胺干混悬剂新增重型再生障碍性贫血适应症 艾尔建美学注射用A型肉毒毒素获批改善中重度额纹 3期试验勃林格殷格翰Gcg/GLP-1双激动剂索弗度肽减重16.6% 首仿，华阳制药第二代JAK抑制剂乌帕替尼缓释片获批 独家剂型，和泽医药甲苯磺酸艾多沙班口崩片获批上市 山东威高宝龄富锦合作降磷药物枸橼酸铁胶囊获批上市 相关内容只作为药物研发的参信息。不构成任何与用药咨询有关的建议。 如需发稿，您可通过在药研苑公众号下以发送信息的方式将官网或官方公众号的稿件链接和标题发送给我们。我们将择优确定是否发布。